Biological and Clinical Characterization of Novel lncRNAs Associated with Metastatic Prostate Cancer
Annual rept. 15 Aug 2013-14 Aug 2014
MICHIGAN UNIV REGENTS ANN ARBOR DIV OF RESEARCH DEVELOPMENT AND ADMINISTRATION
Pagination or Media Count:
LncRNA are polyadenylated RNA species that are more than 200bp in length and are implicated in development of variety of cancers including prostate cancer. In this study we have identified PCAT29 as the first androgen receptor repressed lncRNA that functions as a tumor suppressor. We show that loss of PCAT29 may identify a subset of patients at higher risk for disease recurrence. Collectively, PCAT29 is a tumor-suppressive lncRNA of prognostic and therapeutic relevance in prostate cancer. In addition, we have performed transcriptome analysis to identify a set of AR regulated lncRNAs. AR plays a critical role in the development and progression of prostate cancer. AR regulates a large repertoire of genes however, its role in Long non-coding RNAs lncRNA regulation remains unclear. With this compendium of AR regulated lncRNA, we will be able to identify lncRNAs that play important role in prostate cancer development and progression.
- Genetic Engineering and Molecular Biology
- Medicine and Medical Research